Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.69 EUR | -3.34% | -4.06% | -54.29% |
05-08 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
05-08 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
Evolution of the average Target Price on EyePoint Pharmaceuticals, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering EyePoint Pharmaceuticals, Inc.
Baird | |
Chardan Research | |
Mizuho Securities | |
JPMorgan Chase | |
Capital One Securities | |
HC Wainwright | |
JonesTrading Institutional Services | |
Guggenheim | |
Cowen | |
Cantor Fitzgerald | |
B. Riley |
EPS Revisions
- Stock Market
- Equities
- EYPT Stock
- PV3B Stock
- Consensus EyePoint Pharmaceuticals, Inc.